130 related articles for article (PubMed ID: 19223422)
21. Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide.
Dijkgraaf I; Kruijtzer JA; Frielink C; Corstens FH; Oyen WJ; Liskamp RM; Boerman OC
Int J Cancer; 2007 Feb; 120(3):605-10. PubMed ID: 17096340
[TBL] [Abstract][Full Text] [Related]
22. Imaging of alpha(v)beta(3) expression by a bifunctional chimeric RGD peptide not cross-reacting with alpha(v)beta(5).
Zannetti A; Del Vecchio S; Iommelli F; Del Gatto A; De Luca S; Zaccaro L; Papaccioli A; Sommella J; Panico M; Speranza A; Grieco P; Novellino E; Saviano M; Pedone C; Salvatore M
Clin Cancer Res; 2009 Aug; 15(16):5224-33. PubMed ID: 19671851
[TBL] [Abstract][Full Text] [Related]
23. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients.
Stroomer JW; Roos JC; Sproll M; Quak JJ; Heider KH; Wilhelm BJ; Castelijns JA; Meyer R; Kwakkelstein MO; Snow GB; Adolf GR; van Dongen GA
Clin Cancer Res; 2000 Aug; 6(8):3046-55. PubMed ID: 10955783
[TBL] [Abstract][Full Text] [Related]
24. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide.
Dijkgraaf I; Liu S; Kruijtzer JA; Soede AC; Oyen WJ; Liskamp RM; Corstens FH; Boerman OC
Nucl Med Biol; 2007 Jan; 34(1):29-35. PubMed ID: 17210459
[TBL] [Abstract][Full Text] [Related]
25. Preclinical evaluation of the breast cancer cell-binding peptide, p160.
Askoxylakis V; Zitzmann S; Mier W; Graham K; Krämer S; von Wegner F; Fink RH; Schwab M; Eisenhut M; Haberkorn U
Clin Cancer Res; 2005 Sep; 11(18):6705-12. PubMed ID: 16166451
[TBL] [Abstract][Full Text] [Related]
26. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
[TBL] [Abstract][Full Text] [Related]
27. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting.
van Schaijk FG; Broekema M; Oosterwijk E; van Eerd JE; McBride BJ; Goldenberg DM; Corstens FH; Boerman OC
J Nucl Med; 2005 Jun; 46(6):1016-22. PubMed ID: 15937314
[TBL] [Abstract][Full Text] [Related]
28. Can 111In-RGD2 monitor response to therapy in head and neck tumor xenografts?
Terry SY; Abiraj K; Lok J; Gerrits D; Franssen GM; Oyen WJ; Boerman OC
J Nucl Med; 2014 Nov; 55(11):1849-55. PubMed ID: 25349221
[TBL] [Abstract][Full Text] [Related]
29. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer.
de Bree R; Roos JC; Quak JJ; den Hollander W; Snow GB; van Dongen GA
Clin Cancer Res; 1995 Jun; 1(6):591-8. PubMed ID: 9816020
[TBL] [Abstract][Full Text] [Related]
30. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis.
Chen X; Park R; Shahinian AH; Tohme M; Khankaldyyan V; Bozorgzadeh MH; Bading JR; Moats R; Laug WE; Conti PS
Nucl Med Biol; 2004 Feb; 31(2):179-89. PubMed ID: 15013483
[TBL] [Abstract][Full Text] [Related]
31. Study on biodistribution and imaging of radioiodinated arginine-arginine-leucine peptide in nude mice bearing human prostate carcinoma.
Yu M; Zhou H; Liu X; Huo Y; Zhu Y; Chen Y
Ann Nucl Med; 2010 Jan; 24(1):13-9. PubMed ID: 19997991
[TBL] [Abstract][Full Text] [Related]
32. targeted drug delivery to hepatocarcinoma in vivo by phage-displayed specific binding peptide.
Du B; Han H; Wang Z; Kuang L; Wang L; Yu L; Wu M; Zhou Z; Qian M
Mol Cancer Res; 2010 Feb; 8(2):135-44. PubMed ID: 20145035
[TBL] [Abstract][Full Text] [Related]
33. A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expression.
Cai W; Zhang X; Wu Y; Chen X
J Nucl Med; 2006 Jul; 47(7):1172-80. PubMed ID: 16818952
[TBL] [Abstract][Full Text] [Related]
34. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
35. Isolation of a peptide for targeted drug delivery into human head and neck solid tumors.
Hong FD; Clayman GL
Cancer Res; 2000 Dec; 60(23):6551-6. PubMed ID: 11118031
[TBL] [Abstract][Full Text] [Related]
36. Preparation and characterization of 99mTc(CO)3-BPy-RGD complex as alphav beta3 integrin receptor-targeted imaging agent.
Zhang X; Chen X
Appl Radiat Isot; 2007 Jan; 65(1):70-8. PubMed ID: 17011200
[TBL] [Abstract][Full Text] [Related]
37. Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts.
Verel I; Heider KH; Siegmund M; Ostermann E; Patzelt E; Sproll M; Snow GB; Adolf GR; van Dongen GA
Int J Cancer; 2002 May; 99(3):396-402. PubMed ID: 11992408
[TBL] [Abstract][Full Text] [Related]
38. MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide.
Chen X; Park R; Tohme M; Shahinian AH; Bading JR; Conti PS
Bioconjug Chem; 2004; 15(1):41-9. PubMed ID: 14733582
[TBL] [Abstract][Full Text] [Related]
39. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors.
Behr TM; Jenner N; Béhé M; Angerstein C; Gratz S; Raue F; Becker W
J Nucl Med; 1999 Jun; 40(6):1029-44. PubMed ID: 10452322
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors.
Okarvi SM; Al Jammaz I
Nucl Med Biol; 2010 Apr; 37(3):277-88. PubMed ID: 20346867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
